Balyasny Asset Management
ANIP icon

Balyasny Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Balyasny Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-205,089
Closed -$16.2M – 2862
2025
Q4 		$16.2M Sell
205,089
-81,060
-28% -$7.02M 0.02% 825
2025
Q3 		$26.2M Buy
286,149
+276,233
+2,786% +$22.5M 0.03% 597
2025
Q2 		$647K Buy
+9,916
New +$646K ﹤0.01% 2199
2025
Q1 		– Sell
-38,488
Closed -$2.14M – 2767
2024
Q4 		$2.14M Buy
+38,488
New +$2.21M ﹤0.01% 1648
2024
Q3 		– Sell
-12,039
Closed -$767K – 2716
2024
Q2 		$767K Buy
+12,039
New +$782K ﹤0.01% 1892
2024
Q1 		– Sell
-5,311
Closed -$293K – 2586
2023
Q4 		$293K Buy
+5,311
New +$292K ﹤0.01% 2171
2022
Q4 		– Sell
-138,949
Closed -$4.47M – 2750
2022
Q3 		$4.47M Buy
+138,949
New +$4.76M 0.01% 1062
2015
Q3 		– Sell
-7,730
Closed -$480K – 1138
2015
Q2 		$480K Buy
+7,730
New +$460K ﹤0.01% 865

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management's ANIP Position: Q1 2026 in Review

Balyasny Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 205,089 shares — an estimated $16.2M sold.

Balyasny Asset Management first reported a position in ANIP in Q2 2015 and held it in 8 quarters. The position peaked at $26.2M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Balyasny Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 205,089 ANI Pharmaceuticals shares in Q1 2026, an estimated $16.2M.
  • Balyasny Asset Management first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • Balyasny Asset Management's ANI Pharmaceuticals position peaked at $26.2M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.